KR20240151737A - 이작용성 설폰아미드 화합물 - Google Patents

이작용성 설폰아미드 화합물 Download PDF

Info

Publication number
KR20240151737A
KR20240151737A KR1020247024222A KR20247024222A KR20240151737A KR 20240151737 A KR20240151737 A KR 20240151737A KR 1020247024222 A KR1020247024222 A KR 1020247024222A KR 20247024222 A KR20247024222 A KR 20247024222A KR 20240151737 A KR20240151737 A KR 20240151737A
Authority
KR
South Korea
Prior art keywords
optionally substituted
compound
alkyl
cycloalkyl
mmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247024222A
Other languages
English (en)
Korean (ko)
Inventor
마틴 브르조조프스키
장-마르크 다니엘 가르니에
크리스토퍼 가드너
기욤 로랑 레센
빌헬무스 요하네스 안토니우스 케르스텐
Original Assignee
아낙시스 파마 피티와이 엘티디
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2021904204A external-priority patent/AU2021904204A0/en
Application filed by 아낙시스 파마 피티와이 엘티디 filed Critical 아낙시스 파마 피티와이 엘티디
Publication of KR20240151737A publication Critical patent/KR20240151737A/ko
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/427Thiazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965Non-condensed pyrazines
    • A61K31/497Non-condensed pyrazines containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
KR1020247024222A 2021-12-22 2022-12-22 이작용성 설폰아미드 화합물 Pending KR20240151737A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2021904204A AU2021904204A0 (en) 2021-12-22 Bifunctional sulphonamide compounds
AU2021904204 2021-12-22
PCT/AU2022/051575 WO2023115149A1 (en) 2021-12-22 2022-12-22 Bifunctional sulphonamide compounds

Publications (1)

Publication Number Publication Date
KR20240151737A true KR20240151737A (ko) 2024-10-18

Family

ID=86900865

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247024222A Pending KR20240151737A (ko) 2021-12-22 2022-12-22 이작용성 설폰아미드 화합물

Country Status (9)

Country Link
US (1) US20250074891A1 (https=)
EP (1) EP4452966A4 (https=)
JP (1) JP2025501765A (https=)
KR (1) KR20240151737A (https=)
CN (1) CN119013268A (https=)
AU (1) AU2022420983A1 (https=)
CA (1) CA3241593A1 (https=)
MX (1) MX2024007883A (https=)
WO (1) WO2023115149A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025096550A1 (en) * 2023-10-31 2025-05-08 Twine Therapeutics, Inc. Methods of treating cardiomyopathy
WO2025155642A1 (en) * 2024-01-21 2025-07-24 The Regents Of The University Of California Dcaf16-based covalent handle for the rational design of monovalent degraders

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2948544A1 (en) * 2014-05-15 2015-11-19 Catalyst Therapeutics Pty Ltd Methods for inhibiting necroptosis
CA2976121A1 (en) * 2015-02-10 2016-08-18 Catalyst Therapeutics Pty Ltd Inhibitors of necroptosis
WO2018192416A1 (en) * 2017-04-17 2018-10-25 National Institute Of Biological Sciences, Beijing Treating Male Senescence
CN114521196A (zh) * 2019-09-16 2022-05-20 诺华股份有限公司 双官能团降解剂及其使用方法
DK4168401T3 (da) * 2020-06-19 2026-04-13 Anaxis Pharma Pty Ltd Sulfonamidforbindelser

Also Published As

Publication number Publication date
US20250074891A1 (en) 2025-03-06
WO2023115149A1 (en) 2023-06-29
CA3241593A1 (en) 2023-06-29
CN119013268A (zh) 2024-11-22
AU2022420983A1 (en) 2024-07-04
JP2025501765A (ja) 2025-01-23
EP4452966A4 (en) 2025-12-17
EP4452966A1 (en) 2024-10-30
MX2024007883A (es) 2024-09-23

Similar Documents

Publication Publication Date Title
CN109310671B (zh) 布鲁顿酪氨酸激酶抑制剂
JP7769648B2 (ja) スルホンアミド化合物
AU2013216721A1 (en) Modulators of methyl modifying enzymes, compositions and uses thereof
JP2012102121A (ja) キナーゼ阻害剤
KR20150001734A (ko) 3-아릴-5-치환-이소퀴놀린-1-온 화합물 및 그의 치료적 용도
JP7219902B2 (ja) ブルトン型チロシンキナーゼ阻害剤
JP2020523328A (ja) Syk阻害薬及びその使用方法
KR20240151737A (ko) 이작용성 설폰아미드 화합물
KR20240148322A (ko) 이작용성 아릴설폰아미드 화합물
CN116981458A (zh) 具有四氢吲哚-1-甲酰胺作为bcl-2抑制剂的化合物
AU2021290652A1 (en) Amido compounds
KR20240150419A (ko) 아릴설폰아미드 화합물
CN121085992A (zh) 信号转导及转录激活蛋白6选择性降解剂化合物
BR112018014705B1 (pt) Compostos inibidores de tirosina quinase de Bruton e composição farmacêutica

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20240718

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application